Katy Trent

Statistics

Publications

Citations

988

H-Index

Active since

2004

Affiliations

Forma Therapeutics (United States)(Current)

Katy Trent is an author at Forma Therapeutics (United States) specializing in cancer pharmacology, molecular oncology, and rna polymerase i regulation.

Publications per year

2004–2010

Publications

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Denis Drygin, Adam Siddiqui-Jain, Sean O’Brien et al. · Cancer Research · 2009 · 594 citations

Life Sciences, Molecular Biology, Oncology +17

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90

Jean‐Yves Le Brazidec, Adeela Kamal, David J. Busch et al. · Journal of Medicinal Chemistry · 2004 · 84 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Quarfloxin (CX-3543) disrupts the Nucleolin/ rDNA quadruplex complexes, inhibits the elongation by RNA Polymerase I and exhibits potent antitumor activity in models of cancer

Denis Drygin, Jeffrey Whitten, William G. Rice et al. · Cancer Research · 2008 · 11 citations

Life Sciences, Molecular Biology, Oncology +16

1–4 of 4